(Q36466764)

14 August 2017

title

Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders (English)

1 reference

14 August 2017

Ursula C Brewster

1

1 reference

14 August 2017

Marc A Ciampi

series ordinal

2

1 reference

14 August 2017

Ali K Abu-Alfa

series ordinal

3

1 reference

14 August 2017

Robert F Reilly

series ordinal

4

1 reference

14 August 2017

publication date

1 April 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

142-146

1 reference

Current treatment strategies in ANCA-positive renal vasculitis-lessons from European randomized trials

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Susceptibility genes for hypertension and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Disturbances of acid-base balance and bone disease in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Arterial stiffening and vascular calcifications in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00544.X

10.1111/J.1440-1797.2006.00544.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference